FDA's New Diabetes Drug Warning Includes Meds from J&J, AstraZeneca, Lilly
The U.S. FDA has warned that sodium-glucose cotransporter-2 (SGLT2) inhibitors -- a class of type 2 diabetes drugs -- can lead to ketoacidosis.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Diabetes | Diabetes Type 2 | Endocrinology | Pharmaceuticals | SGLT2 Inhibitors | Warnings